"Plus, there are possibly more attractive opportunities in other health companies at the moment"
That entirely depends on your sentiment about success with deals, the 2nd read-out and the full trial outcomes.
If they fail, yes, there are many better opportunities. But if they all succeed, you are unlikely to find a better biotech opportunity than this at the moment.
Until things are clearer, the market will ebb and flow with the changing balance between belief and doubt.
Ann: Investor Presentation, page-114
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $222.9M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 43.0¢ | 39.8¢ | $436.4K | 1.067M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24999 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 11224 | 1 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |